Role of Cytosorb in Left Ventricular Assist Device Implantation — CYCLONE-LVAD  

Heart Failure Clinical Trial

Official title: CYtosorb Modulation of surgiCal infLammatiON During LVAD insErtion

Status Recruiting

Clinical Trial Summary

Mechanical circulatory support, specifically implantable continuous flow left ventricular assist device (CF-LVAD) therapy has been established as a viable treatment for rapidly deteriorating patients suffering from end stage heart failure either as bridge or alternative to heart transplantation. However, a large proportion of these patients experience severe complications in the early postoperative period including right ventricular failure or multi organ failure leading to increased mortality. The leading theory explaining these complications involves exaggerated systemic inflammatory response prior to, during and early after CF-LVAD insertion. Among the cytokines IL-6 appears to play a major role. There is increasing demonstration of the efficacy of a cytokine haemoadsorption (HA) technology in attenuating cytokine response and particularly IL-6 in various inflammatory states and emerging data on the safety of the Cytosorb® device in routine and complex cardiac surgery.

The study team hypothesizes that Cytosorb® treatment is feasible and safe in heart failure patients undergoing LVAD insertion and that it is effective in attenuating IL-6 secretion with benefit in the wider inflammatory and metabolic response to this high-risk surgery.

Clinical Trial Description

The principle objectives of this study are:

1. To investigate the efficacy of Cytosorb® treatment in attenuating perioperative changes in IL-6 during CF-LVAD implantation

2. To investigate the feasibility, and safety of Cytosorb® treatment during CF-LVAD implantation.

3. To pilot the effect of Cytosorb® treatment on vasoplegia and organ dysfunction with specific focus on right ventricle failure, liver failure and acute kidney injury (AKI).

4. To establish a collaborative biobank of patient's biological samples to allow extensive characterisation of patient phenotype prior to CF-LVAD implantation and their individual inflammatory and metabolic responses to surgery and perioperative management. ;

Related Conditions & MeSH terms

• Heart Failure

• NCT number: NCT04596813
• Study type: Interventional
• Source: Imperial College London
• Contact: Nandor Marczin
• Phone: +44 1895 823 737
• Email: n.marczin@imperial.ac.uk
• Status: Recruiting
• Phase: N/A
• Start date: September 21, 2020
• Completion date: June 30, 2025